|Assessment Status||Rapid Review Complete|
|Indication||As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).|
|Rapid review commissioned||09/09/2014|
|Rapid review completed||15/09/2014|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.